• Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com Investing.com Nigeria Thu, 09 Jul 2026 02:00:34 GMT
• Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options Stock Titan Thu, 09 Jul 2026 01:42:47 GMT
• Cellectar Biosciences (CLRB) director granted 37,500 stock options Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Cellectar Biosciences (CLRB) director awarded 25,000 options at $2.70 strike Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Cellectar (CLRB) awards director Andrew Gu 25,000 options Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Cellectar Biosciences (CLRB) director receives grant of 25,000 stock options Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Cellectar Biosciences (CLRB) grants COO 118,000 stock options Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Cellectar (CLRB) director receives 25,000 stock options at $2.70 strike Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Cellectar (CLRB) CFO awarded 92,000 stock options at $3.14 strike price Stock Titan Thu, 09 Jul 2026 01:42:46 GMT
• Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options Stock Titan Thu, 09 Jul 2026 01:04:30 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data Stocktwits Fri, 03 Jul 2026 21:35:02 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data Stocktwits Sat, 27 Jun 2026 12:39:23 GMT
• price to book forward of cellectar biosciences, inc. – nasdaq:clrb TradingView Sat, 27 Jun 2026 06:56:55 GMT
• enterprise value to ebit forward of cellectar biosciences, inc. – nasdaq:clrb TradingView Fri, 26 Jun 2026 16:01:02 GMT
• cellectar biosciences, inc. actuals & estimates (nasdaq:clrb) TradingView Fri, 26 Jun 2026 07:05:53 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data Stocktwits Sun, 21 Jun 2026 12:37:38 GMT
• 12 health care stocks moving in thursday's after-market session Benzinga Thu, 18 Jun 2026 21:06:27 GMT
• cellectar biosciences inc (clrb) shareholder structure: major shareholders & institutional holdings TradingKey Thu, 18 Jun 2026 09:29:57 GMT
• cellectar biosciences inc (clrb) earnings forecast: future eps & revenue growth estimates TradingKey Thu, 18 Jun 2026 09:00:33 GMT
• cellectar biosciences inc (clrb) technical analysis: support, resistance, indicators & moving averages TradingKey Thu, 18 Jun 2026 08:56:52 GMT
• cellectar biosciences inc (clrb) dividends & stock splits: historical payouts and event timeline TradingKey Thu, 18 Jun 2026 05:55:02 GMT
• Cellectar Biosciences Inc (CLRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution TradingKey Thu, 18 Jun 2026 05:31:29 GMT
• cellectar biosciences inc (clrb) financial health: profitability & balance sheet analysis TradingKey Thu, 18 Jun 2026 05:02:57 GMT
• cellectar biosciences inc (clrb) institutional confidence TradingKey Thu, 18 Jun 2026 01:09:52 GMT
• cellectar biosciences (clrb) edges higher: consolidation near key resistance - fund manager survey newsline.com Thu, 18 Jun 2026 00:40:42 GMT
• cellectar biosciences inc (clrb) risk assessment: volatility, financial risk & investment risk TradingKey Wed, 17 Jun 2026 21:27:20 GMT
• cellectar biosciences inc (clrb) valuation: pe, pb & fair value analysis TradingKey Wed, 17 Jun 2026 20:54:13 GMT
• CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises Market - Profit Recovery Report dars.gov.et Wed, 17 Jun 2026 07:00:00 GMT
• cellectar biosciences inc (clrb) valuation: pe, pb & fair value analysis TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• cellectar biosciences inc (clrb) risk assessment: volatility, financial risk & investment risk TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data Stocktwits Sat, 13 Jun 2026 16:29:17 GMT
• clrb q1 2026 earnings: eps beat on narrower loss, stock slips - revenue guidance range newsline.com Sat, 13 Jun 2026 04:43:28 GMT
• clrb q1 2026 earnings: narrower-than-expected loss highlights cost management amid pipeline progress newsline.com Fri, 12 Jun 2026 14:31:15 GMT
• number of shareholders of cellectar biosciences, inc. – mun:nv40 TradingView Fri, 12 Jun 2026 11:49:27 GMT
• CLRB Q1 2026 Earnings: EPS Beat on Narrower Loss, Stock Slips - Earnings Sentiment Score dars.gov.et Fri, 12 Jun 2026 07:00:00 GMT
• clrb q1 2026 earnings: narrower-than-expected loss offers some respite as preclinical pipeline advances - profit recovery report newsline.com Wed, 10 Jun 2026 17:30:37 GMT
• Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing Stock Titan Tue, 09 Jun 2026 07:00:00 GMT
• clrb q1 2026 earnings: narrower-than-expected loss as biotech advances pipeline - quarterly profit report newsline.com Tue, 09 Jun 2026 05:44:08 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data Stocktwits Fri, 05 Jun 2026 13:52:34 GMT
• Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) Stock Titan Fri, 05 Jun 2026 07:00:00 GMT
• cellectar biosciences (clrb) q1 2026 earnings: narrower loss beats estimates as pipeline progress continues - profit announcement newsline.com Wed, 03 Jun 2026 07:00:00 GMT
• tue healthcare report: cellectar biosciences touting new clinical trial data for cancer therapy WisBusiness Tue, 02 Jun 2026 14:41:56 GMT
• Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named Stock Titan Tue, 02 Jun 2026 07:00:00 GMT
• Cellectar Biosciences to Highlight Compelling New Efficacy GlobeNewswire Mon, 01 Jun 2026 07:00:00 GMT
• Iopofosine data: 16-month responses in Waldenström spur phase 3 plan Stock Titan Mon, 01 Jun 2026 07:00:00 GMT
• cellectar plans phase 3 trial for wm treatment after btki Investing.com Mon, 01 Jun 2026 07:00:00 GMT
• cellectar biosciences (clrb) fda approvals, pdufa dates & drug alerts 2026 $clrb MarketBeat Mon, 01 Jun 2026 07:00:00 GMT
• cellectar (nasdaq: clrb) details 51.9m-share resale tied to may 2026 financing Stock Titan Fri, 29 May 2026 12:50:22 GMT
• cellectar biosciences stock drops 17% on $5.8m fundraise: retail awaits an ‘impending’ rally MSN Fri, 29 May 2026 09:40:15 GMT
• CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline - Management Guidance Update dars.gov.et Fri, 29 May 2026 07:00:00 GMT
• cellectar biosciences (clrb) upgraded to buy: here's what you should know MSN Fri, 29 May 2026 00:56:24 GMT
• clrb q1 2026 earnings: narrower-than-expected loss per share drives positive stock reaction - revenue report newsline.com Thu, 28 May 2026 07:00:00 GMT
• cellectar biosciences (clrb) edges higher: support levels tested as biotech sector shows mixed signals - virgin poc newsline.com Thu, 28 May 2026 07:00:00 GMT
• large warrant exercise and equity plan votes ahead for cellectar (nasdaq: clrb) Stock Titan Thu, 28 May 2026 07:00:00 GMT
• clrb q1 2026 earnings: narrower-than-expected loss amid no revenue - positive surprise momentum newsline.com Mon, 25 May 2026 07:00:00 GMT
• cellectar biosciences edges higher, finding support near $3.04 - percent below ma newsline.com Mon, 25 May 2026 07:00:00 GMT
• cellectar biosciences stock jumps after fda grants rare pediatric disease designation MSN Sun, 24 May 2026 16:18:27 GMT
• clrb q1 2026 earnings: narrower-than-expected loss drives positive sentiment - banking earnings report lwvtexas.org Sun, 24 May 2026 07:00:00 GMT
• cellectar biosciences stock jumps after fda grants rare pediatric disease designation MSN Sat, 23 May 2026 16:47:16 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data MSN Thu, 21 May 2026 14:29:47 GMT
• cellectar biosciences announces board changes and new director The Globe and Mail Tue, 19 May 2026 22:16:00 GMT
• cellectar (nasdaq: clrb) s-1 details 51.2m-share resale and major warrant overhang Stock Titan Tue, 19 May 2026 21:05:41 GMT
• cellectar (clrb) delivers q1 2026 beat — eps $-1.30 vs $-1.92 expected - low growth earnings newsline.com Tue, 19 May 2026 07:00:00 GMT
• cellectar biosciences files for secondary offering of common shares Moomoo Tue, 19 May 2026 07:00:00 GMT
• cellectar biosciences announces board changes and new director TipRanks Mon, 18 May 2026 22:03:56 GMT
• cellectar biosciences appoints andrew gu to board; stefan d. loren to step down, join as consultant TradingView Mon, 18 May 2026 20:23:01 GMT
• cellectar biosciences, inc. announces board changes marketscreener.com Mon, 18 May 2026 07:00:00 GMT
• cellectar (nasdaq: clrb) reshapes board with loren exit and andrew gu appointment Stock Titan Mon, 18 May 2026 07:00:00 GMT
• cellectar biosciences (nasdaq: clrb) seeks approval for warrants and plan increase Stock Titan Mon, 18 May 2026 07:00:00 GMT
• cellectar biosciences (clrb) price target decreased by 25.00% to 10.71 MSN Sun, 17 May 2026 12:35:27 GMT
• user | dailytimesleader.com - cellectar biosciences, inc. - common stock (nasdaq:clrb) stock quote FinancialContent Sun, 17 May 2026 11:32:27 GMT
• cellectar (clrb) phase 2b data shows durable responses in waldenström macroglobulinemia MSN Sun, 17 May 2026 10:36:57 GMT
• cellectar biosciences (clrb) price target decreased by 25.00% to 10.71 MSN Sat, 16 May 2026 03:33:06 GMT
• maxim group maintains cellectar biosciences(clrb.us) with buy rating, maintains target price $10 Moomoo Fri, 15 May 2026 13:31:00 GMT
• cellectar biosciences, inc. q1 2026 financial report, forward-looking statements, and sec filings Minichart Fri, 15 May 2026 07:00:00 GMT
• cellectar biosciences, inc. (nasdaq:clrb) q1 2026 earnings call transcript Insider Monkey Fri, 15 May 2026 07:00:00 GMT
• cellectar biosciences reports positive phase 2b data for iopofosine i 131 in waldenström macroglobulinemia and secures $140m finan... Minichart Fri, 15 May 2026 07:00:00 GMT
• key facts: cellectar iopofosine 83.6% orr; $140m raise, q1 loss $5.65m TradingView Fri, 15 May 2026 07:00:00 GMT
• cellectar biosciences, inc. - common stock (nq: clrb FinancialContent Fri, 15 May 2026 05:02:37 GMT
• cellectar biosciences inc (clrb) q1 2026 earnings call highlights: strategic advances amid financial challenges GuruFocus Fri, 15 May 2026 01:18:45 GMT
• cellectar biosciences signals pivotal turn in earnings call TipRanks Fri, 15 May 2026 00:36:51 GMT
• cellectar biosciences (clrb) price target decreased by 25.00% to 10.71 MSN Thu, 14 May 2026 23:39:20 GMT
• cellectar biosciences (clrb) reports positive phase iib results and plans fda filing GuruFocus Thu, 14 May 2026 21:33:45 GMT
• cellectar biosciences, inc. q1 2026 financial report, forward-looking statements, and sec filings Minichart Thu, 14 May 2026 20:45:00 GMT
• cellectar plans phase iii start in late q4 2026 as it outlines potential wm approval in the second half of 2027 MSN Thu, 14 May 2026 16:59:22 GMT
• cellectar biosciences reports positive phase 2b data for iopofosine i 131 in waldenström macroglobulinemia and secures $140m finan... Minichart Thu, 14 May 2026 16:43:00 GMT
• is cellectar biosciences (clrb) attractively valued after q1 202 GuruFocus Thu, 14 May 2026 15:22:30 GMT
• cellectar (clrb) secures $140 million financing for regulatory m GuruFocus Thu, 14 May 2026 13:18:45 GMT
• cellectar biosciences reports q1 eps ($1.33), consensus ($1.88) TipRanks Thu, 14 May 2026 13:00:29 GMT
• full transcript: cellectar biosciences q1 2026 earnings call Benzinga Thu, 14 May 2026 12:59:38 GMT
• cellectar biosciences, inc. reports earnings results for the first quarter ended march 31, 2026 marketscreener.com Thu, 14 May 2026 11:01:00 GMT
• Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary Yahoo Finance Thu, 14 May 2026 07:00:00 GMT
• Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Yahoo Finance Thu, 14 May 2026 07:00:00 GMT
• Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share AlphaStreet Thu, 14 May 2026 07:00:00 GMT
• CLRB: Strong efficacy in r/r WM and robust financing position clinical programs for key milestones TradingView Thu, 14 May 2026 07:00:00 GMT
• cancer-drug maker cellectar lines up up to $140m for waldenström trial, fda bid Stock Titan Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences reports q1 2026 net loss of $5.65m; cash $8.3m before $31m financing TradingView Thu, 14 May 2026 07:00:00 GMT
• earnings call transcript: cellectar biosciences q1 2026 shows progress Investing.com Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences releases q1 2026 financial results AlphaStreet Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences (clrb) posts q1 2026 loss and secures up to $140m Stock Titan Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences inc reports results for the quarter ended march 31 - earnings summary TradingView Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences, inc. q1 2026: net loss $(5.65m), eps $(1.33) — 10-q summary TradingView Thu, 14 May 2026 07:00:00 GMT
• clrb: strong clinical results and $140m financing drive late-stage execution and regulatory momentum TradingView Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences reports positive 12-month data for iopofosine i 131 in relapsed/refractory waldenström macroglobulinemia and... Quiver Quantitative Thu, 14 May 2026 07:00:00 GMT
• clrb: net loss narrowed, clinical data for iopofosine i 131 remained strong, and $35m was raised for phase 3 TradingView Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences (nasdaq: clrb) posts q1 loss and flags going-concern risk Stock Titan Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences inc (clrb) q1 2026 earnings call highlights: strategic advances amid ... by gurufocus Investing.com Canada Thu, 14 May 2026 07:00:00 GMT
• press release: cellectar biosciences reports first quarter 2026 financial results and provides corporate updates Moomoo Thu, 14 May 2026 07:00:00 GMT
• cellectar biosciences, inc. - common stock (nq: clrb FinancialContent Wed, 13 May 2026 14:57:08 GMT
• cellectar biosciences rolls out new clinical trial data for cancer therapy WisBusiness Wed, 13 May 2026 07:00:00 GMT
• Cellectar Biosciences Inc expected to post a loss of $1.88 a share - Earnings Preview TradingView Tue, 12 May 2026 07:00:00 GMT
• cellectar biosciences coo jarrod longcor buys $24,998 in stock by investing.com Investing.com India Tue, 12 May 2026 07:00:00 GMT
• cellectar biosciences ceo buys $24,998 in company stock by investing.com Investing.com India Tue, 12 May 2026 07:00:00 GMT
• cellectar (nasdaq: clrb) coo boosts stake with common stock and warrant buys Stock Titan Tue, 12 May 2026 00:27:00 GMT
• cellectar (clrb) ceo reports open-market stock and warrant buys Stock Titan Tue, 12 May 2026 00:08:55 GMT
• Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 GlobeNewswire Mon, 11 May 2026 07:00:00 GMT
• why cellectar (clrb) ability to generate cash matters (-0.32%) 2026-05-11 - standard deviation newsline.com Mon, 11 May 2026 07:00:00 GMT
• cellectar biosciences ceo buys $24,998 in company stock Investing.com Mon, 11 May 2026 07:00:00 GMT
• cellectar (nasdaq: clrb) coo boosts stake with common stock and warrant buys Stock Titan Mon, 11 May 2026 07:00:00 GMT
• cellectar (clrb) ceo reports open-market stock and warrant buys Stock Titan Mon, 11 May 2026 07:00:00 GMT
• stonepine, jon plexico disclosed 9.9% stake in cellectar biosciences (clrb) Stock Titan Mon, 11 May 2026 07:00:00 GMT
• cellectar biosciences coo jarrod longcor buys $24,998 in stock Investing.com Mon, 11 May 2026 07:00:00 GMT
• cellectar (clrb) phase 2b data shows durable responses in waldenström macroglobulinemia MSN Sat, 09 May 2026 00:54:59 GMT
• cellectar biosciences inc expected to post a loss of $1.88 a share - earnings preview TradingView Fri, 08 May 2026 15:31:10 GMT
• clrb stock surged 27% today – here’s why retail is bullish about cellectar’s blood cancer trial data MSN Fri, 08 May 2026 09:42:36 GMT
• cellectar (nasdaq: clrb) raises $35m, plans phase 3 wm trial Stock Titan Fri, 08 May 2026 07:00:00 GMT
• cellectar biosciences raises ~$35 million in registered direct and private placement TradingView Fri, 08 May 2026 07:00:00 GMT
• clrb sec filings - cellectar biosciences inc 10-k, 10-q, 8-k forms Stock Titan Fri, 08 May 2026 06:33:39 GMT
Cellectar Biosciences, Inc(NASDAQ:CLRB) 
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refr...
Website: http://www.cellectar.com
Founded: 1996
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology